

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



维亚生物科技控股集团
VIVA BIOTECH HOLDINGS

(Incorporated in the Cayman Islands as an exempted company with limited liability)

(Stock code: 1873)

VOLUNTARY ANNOUNCEMENT GRANT OF RESTRICTED SHARE UNITS

This announcement is made by Viva Biotech Holdings (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that the Company granted restricted share units (the “**RSU(s)**”) to certain eligible participants on June 25, 2026 under the RSU scheme adopted by the Company on June 5, 2020 (the “**RSU Scheme**”), pursuant to which the grantees shall, subject to the terms of the grant, be entitled to up to an aggregate of 6,224,000 ordinary shares of the Company (the “**Share(s)**”).

Details of the RSUs granted are set out below:

Date of Grant:	June 25, 2026 (the “ Date of Grant ”)
Number and description of grantees:	43 persons being employees of the Group, the grantees are core members to the Group’s contract development manufacture organization (CDMO) operations, none of them are Director, chief executive or substantial shareholder of the Company or an associate of any of them
Number of RSUs granted:	6,224,000 RSU (each RSU shall, subject to the terms of the grant, entitle the grantee to one Share upon vesting).
Closing price of the Shares underlying RSUs on the Date of Grant:	HK\$1.08
Vesting dates of the RSUs:	Subject to vesting conditions including performance target of both the Group and the grantee, (i) 40% of RSUs granted to each grantee shall be vested on June 25, 2028, (ii) 30% of the RSUs granted to each grantee shall be vested on June 25, 2029, and (iii) the remaining 30% shall be vested on June 25, 2030.

Performance target:	The Group's performance target for the three tranches of RSUs referred to in the preceding paragraph is that the Group's revenue for the 2027, 2028 and 2029 financial year as recorded in the Company's audited consolidated financial statements shall increase by no less than 35%, 55% and 75% as compared to the Group's revenue for the 2025 financial year, respectively. The grant is further subject to a tiered individual performance target based on the comprehensive annual appraisal results of the employees.
Purchase price payable by the grantee:	The grant is further conditional upon the grantee's payment of a purchase price of HK\$1.08 per RSU at the time when the RSUs become vested.

In relation to the above grants, the Company shall direct and procure the trustee of the trust set up for the RSU Scheme to release from the trust the Shares to the grantees upon the satisfaction of all vesting conditions. Subsequent to the grant of the RSUs, the number of Shares available for future grant pursuant to the RSU Scheme is 6,016,000 Shares. The RSU Scheme is funded solely by existing Shares and will not involve the issuance of new Shares or the use of treasury Shares. The RSU Scheme therefore constitute a share scheme under Chapter 17 of the Listing Rules and shall be subject to the applicable disclosure requirements under Rule 17.12 of the Listing Rules. It is however not subject to the other requirements under Chapter 17 of the Listing Rules.

By order of the Board
Viva Biotech Holdings
Mao Chen Cheney
Chairman and Chief Executive Officer

Hong Kong, June 25, 2026

As at the date of this notice, the Board comprises three Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. Wu Ying and Mr. Ren Delin; one Non-executive Director, namely, Mr. Wu Yuting; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.